A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04).
Salani R, McCormack M, Kim YM, Ghamande S, Hall SL, Lorusso D, Barraclough L, Gilbert L, Guzman Ramirez A, Lu CH, Sabatier R, Colombo N, Hu Y, Krishnan V, Molinero L, Feng Y, Kim N, Castro M, Lin YG, Monk BJ.
Salani R, et al. Among authors: kim ym.
Int J Gynecol Cancer. 2024 Jun 10:ijgc-2024-005588. doi: 10.1136/ijgc-2024-005588. Online ahead of print.
Int J Gynecol Cancer. 2024.
PMID: 38858106